Pass or Fail? ARB for Atrial Fibrillation Recurrence

The Libin Cardiovascular Institute of Alberta‘s Dr. Anne Gillis, Professor of Medicine, a scholar of the Alberta Heritage Foundation for Medical Research and the Medical Director of Cardiac Pacing and Electrophysiology, wrote an editorial in the New England Journal of Medicine on the topic of Angiotensin-Receptor Blockers for Prevention of Atrial Fibrillation.

ag1

New England Journal of Medicine editorial by Dr. Gillis – LINK

New England Journal of Medicine – study by Marcello Diertori et al. – LINK

MedPage Today interviewed Dr. Gillis on this study, and on her comments in the editorial. Following is an excerpt:

But these results, from the first large, prospective randomized trial, “appear to provide strong evidence that valsartan (Diovan) and possibly other ARBs do not prevent the recurrence of atrial fibrillation in this patient population,” she said.

Since only 7.9% of study participants had heart failure or left ventricular systolic dysfunction — a population that might have benefited most, according to earlier studies — the results from this trial can’t be extrapolated to those patients, Dr. Gillis added.

To read the rest of the article, and also to hear a recording of an interview with Dr. Gillis, go to MedPage TodayLINK

Additional coverage:

ForbesLINK
(include quotes from Dr. Anne Gillis)

Heart WireLINK
(include quotes from Dr. Anne Gillis and Dr. D. George Wyse)

Cardio BriefLINK
(include quotes from Dr. Anne Gillis)

Health NewsLINK
(include quotes from Dr. Anne Gillis)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s